Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy Journal Article
| Authors: | Kelly, K. J.; Wong, J.; Fong, Y. |
| Article Title: | Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy |
| Abstract: | Background: Patients with hepatic malignancy have a dismal prognosis with standard therapies. NV1020 is an oncolytic herpes simplex virus that has potential to be a safe and effective therapeutic agent for this disease. Objective: We set out to discuss the development of NV1020 as an oncolytic agent and explore the potential role of this particular virus in the setting of human hepatic cancer. Methods: The scope of this review includes an overview of preclinical experience with NV1020, as well as an examination of current standard and developing therapies for liver cancer. The primary focus, however, is on the safety and potential clinical efficacy of NV1020 against hepatic malignancy. Results/conclusion: We have found that NV1020 is a safe, novel therapeutic agent for treatment of refractory hepatic malignancy. © 2008 Informa UK Ltd. |
| Keywords: | cancer survival; survival rate; clinical trial; drug tolerability; review; cancer recurrence; bevacizumab; fluorouracil; drug efficacy; drug potentiation; drug safety; nonhuman; side effect; unspecified side effect; clinical trials as topic; liver neoplasms; drug megadose; antineoplastic agent; colorectal cancer; protein blood level; animals; granulocyte macrophage colony stimulating factor; antineoplastic activity; drug screening; cetuximab; irinotecan; monoclonal antibody; panitumumab; drug dose escalation; fever; drug fatality; liver metastasis; rigor; drug distribution; folinic acid; drug response; long term care; oncolytic herpes virus; simplexvirus; oncolytic virotherapy; drug infusion; drug clearance; single drug dose; liver resection; intermethod comparison; liver cancer; complementary therapies; headache; optimal drug dose; liver function test; maximum tolerated dose; oxaliplatin; gamma glutamyltransferase; radiofrequency ablation; floxuridine; absence of side effects; nv 1020; herpes simplex virus; drug delivery system; virus reactivation; g 207; hsv 1716; oncovex; microwave therapy; yttrium 90; blood chemistry; hepatic malignancy; oncolytic viral therapy; herpes simplex vaccine; hf 10; r 7020; multiple drug dose; capsid proteins |
| Journal Title: | Expert Opinion on Investigational Drugs |
| Volume: | 17 |
| Issue: | 7 |
| ISSN: | 1354-3784 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2008-07-01 |
| Start Page: | 1105 |
| End Page: | 1113 |
| Language: | English |
| DOI: | 10.1517/13543784.17.7.1105 |
| PUBMED: | 18549346 |
| PROVIDER: | scopus |
| PMCID: | PMC3263932 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 4" - "Export Date: 17 November 2011" - "CODEN: EOIDE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work